U.S. Markets closed

OncoSec Medical Incorporated (ONCS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.6900+0.0100 (+0.27%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.6800
Open3.7600
Bid3.6500 x 900
Ask3.9600 x 800
Day's Range3.6000 - 3.7600
52 Week Range1.0400 - 5.4000
Volume60,097
Avg. Volume299,040
Market Cap85.071M
Beta (5Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)-3.0830
Earnings DateDec 06, 2017 - Dec 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.38
  • OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
    PR Newswire

    OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intra-tumoral cancer immunotherapies, today announced that Sandra Aung, Ph.D. joined the Company as Senior Vice President, Chief Clinical Development Officer.

  • OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO™ and Its Gene Delivery Platform
    PR Newswire

    OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO™ and Its Gene Delivery Platform

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intratumoral cancer immunotherapies, today announced the issuance of a new patent covering its interleukin-12 (IL-12) based immunotherapy platform, including its lead product candidate TAVO™. Specifically, on October 6, 2020, the United States Patent and Trademark Office issued U.S. Patent No. 10,792,375, entitled Method for the Treatment of Malignancies, which covers the Company's interleukin-12 (IL-12) based immunotherapy platform, including its lead product candidate TAVO™, and its proprietary EP gene delivery system. This patent covers the use of intratumoral electroporation of DNA encoding interleukins (such as IL-12) to treat cancer and is significant because it is not specific to which type of immune-stimulatory interleukin can be used to treat a patient, nor is it limited to a particular type of cancer.

  • OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus OPDIVO® as Neoadjuvant Therapy for Melanoma
    PR Newswire

    OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus OPDIVO® as Neoadjuvant Therapy for Melanoma

    OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the commencement of an investigator-initiated Phase 2 study led by Senior Member and Professor Ahmad A. Tarhini, M.D., Ph.D. of the H. Lee Moffitt Cancer Center and Research Institute and the University of South Florida Morsani College of Medicine to evaluate its lead product candidate, TAVO™ (interleukin-12 or IL-12 plasmid) immunotherapy as neoadjuvant treatment (administered before surgery) in combination with intravenous OPDIVO® (nivolumab) in up to 33 patients with operable locally/regionally advanced melanoma.